The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.

Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.

A compound having the general structure shown in Formula I:

##STR00001##

or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK.sub.1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.

A compound having the general structure shown in Formula I:

##STR00001##

or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK.sub.1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.

Compounds of formula (I):

##STR00001##

where

##STR00002##

n, R.sup.1, R.sup.4a, R.sup.4b, R.sup.5, R.sup.7 and R.sup.8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.

Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.

Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.

A compound having the general structure shown in Formula I: ##STR00001##
or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK.sub.1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.

A compound having the general structure shown in Formula I: ##STR00001##
or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK.sub.1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.